ArticleOncology research2025
GDF11 downregulates FOXP3 in T-cell acute lymphoblastic leukemia-derived cells and associates with restraining aggressiveness.
Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Growth differentiation factor 11 modulates metabolism, mitigating the pro-tumoral behavior provided by M2-like macrophages in hepatocellular carcinoma-derived cells.World journal of gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Growth differentiation factor 11 (GDF11), a transforming growth factor-beta superfamily member, is a crucial protein involved in many differentiation processes in embryogenesis and morphogenesis, and it has been extensively characterized due to its capacity to target poorly differentiated cells, including transformed or cancer cells. Aim: In the present work, we aimed to describe the effects on migration, proliferation, and metabolism in the T-cell acute lymphoblastic leukemia-derived cell line Jurkat. Methods: Based on previous evidence, we analyzed metabolic changes exerted by GDF11 and its relationship with the aggressive phenotype. Results: We found a profound impact on mitochondrial metabolism and reactive oxygen species content; these were related to a decrement in the expression of the transcription factor forkhead-box-protein P3 (FOXP3), which is highly involved in aggressiveness in leukemia cells; this was verified by a decrement in invasion capacity exhibited by the Jurkat cells under the GDF11 treatment. Conclusion: The results position the GDF11 response as a good alternative in the search for new therapeutic options for these diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.